Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer.
Overview of the Disease IncidencePredictive BiomarkersCurrent General Therapy StandardsAccomplishments During the Year Combined Modality Management of Liver MetastasesTreatment of Advanced Disease Equivalence of FOLFOX and CAPOXAddition of Bevacizumab to Standard ChemotherapyDual EGFR and VEGF InhibitionBevacizumab Upon Progression While on First-Line TherapyBenefit in the Elderly PopulationWhat Needs to be Done Comments on ResearchObstacles to Progress.
Goldberg
Richard M
RM
Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Meropol
Neal J
NJ
Tabernero
Josep
J